CagriSema (Cagrilintide + Semaglutide) CagriSema is a co-formulated combination therapy containing 2.4 mg each of Cagrilintide (a long-acting amylin analog) and Semaglutide (a GLP-1 receptor agonist), administered as a single weekly subcutaneous injection
This is less common in pure weight-loss use than in diabetes care, but it happens, especially in people prescribed Wegovy who also have type 2 diabetes
Tng cng sc khng, min dch cho c th trc nhng yu t tn cng gy hi
That's because some drugs can affect how other drugs work
BMC Womens Health 11, 27 (2011)
NTP Technical Report on the Toxicology and Carcinogenesis Studies of 2, 3, 7, 8-tetracholorodibenzo-p-dioxin 2006)